JGC
MLTX icon

J. Goldman & Co’s MoonLake Immunotherapeutics MLTX Stock Holding History

J. Goldman & Co’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,000
Closed -$527K – 797
2025
Q4 		$527K Buy
+40,000
New +$472K 0.01% 448

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

J. Goldman & Co's MLTX Position: Q1 2026 in Review

J. Goldman & Co increased its MoonLake Immunotherapeutics (MLTX) stake by 35% in Q1 2026, buying an estimated $587K and bringing the position to 136,900 shares worth $2.55M. The position accounts for 0.07% of the portfolio, ranked #285.

J. Goldman & Co first reported a position in MLTX in Q1 2024 and has held it in 6 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • J. Goldman & Co held 136,900 shares of MoonLake Immunotherapeutics worth $2.55M as of Q1 2026.
  • J. Goldman & Co bought 35,433 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $587K.
  • MoonLake Immunotherapeutics made up 0.07% of J. Goldman & Co's portfolio in Q1 2026, its #285 holding.
  • J. Goldman & Co first reported a position in MoonLake Immunotherapeutics in Q1 2024 and has held it in 6 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.